NasdaqGM:CRSPBiotechs
CRISPR Therapeutics (CRSP) Earnings Drew Fresh Interest, Is The Stock Below Fair Value?
CRISPR Therapeutics earnings spark fresh interest in the stock
CRISPR Therapeutics (NasdaqGM:CRSP) is back in focus after reporting second quarter 2026 results on 3 August, with higher revenue of US$10.18 million and a reduced net loss of US$91.15 million.
See our latest analysis for CRISPR Therapeutics.
CRISPR Therapeutics’ latest earnings have arrived alongside a sharp 1 day share price return of 3.64% and a 7 day share price return of 11.52%. However, the 1 month share price return is down...